Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in advanced solid tumors and advanced or metastatic gastric/GEJ adenocarcinoma
CTR20182027Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Nonhematologic neoplasms, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Dec 2018; status: completed.
02
Drugs
cadonilimab
03
Conditions
Nonhematologic neoplasmsgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20182027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182027.